---
schema_version: "secwatch.filing_event.v1"
accession: "0000313143-24-000066"
form_type: "8-K"
ticker: "HAE"
cik: "0000313143"
company_name: "HAEMONETICS CORP"
filed_at: "2024-12-03T23:59:59+00:00"
generated_at: "2026-05-29T10:28:49.810562+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Haemonetics sells whole blood assets to GVS for $44.6M cash plus up to $22.5M earnout

## Summary
- Total consideration up to $67.1M: $44.6M cash at close plus up to $22.5M contingent on sales growth and milestones.
- Assets sold include whole blood collection, processing, and filtration portfolio, plus Covina, CA manufacturing facility and Tijuana, Mexico equipment.
- Haemonetics retains its apheresis line for automated blood collection (platelets, plasma, red cells).
- Transaction expected to close in Q1 2025, subject to customary closing conditions.
- GVS (not publicly traded) is a filter-solutions manufacturer in healthcare and life sciences.

## SEC filing metadata
- accession: 0000313143-24-000066
- form_type: 8-K
- ticker: HAE
- cik: 0000313143
- company_name: HAEMONETICS CORP
- filed_at: 2024-12-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/313143/000031314324000066/0000313143-24-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/313143/000031314324000066/hae-20241203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000313143-24-000066
- JSON: https://secwatch.observer/filing/0000313143-24-000066.json
- Plain text: https://secwatch.observer/filing/0000313143-24-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.